Afatinib Oral Tablet

DRUG2 trials

Sponsors

National Taiwan University Hospital, Merus N.V.

Conditions

Head and Neck NeoplasmsMetastatic Castration-resistant Prostate CancerNSCLC Harboring NRG1 Fusion

Phase 2

Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)

CompletedNCT03695510

National Taiwan University HospitalHead and Neck Neoplasms

Start: 2019-01-24End: 2022-04-14Updated: 2022-04-21

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

TerminatedNCT05588609

Merus N.V.Metastatic Castration-resistant Prostate Cancer, NSCLC Harboring NRG1 Fusion

Start: 2022-11-17End: 2025-07-03Updated: 2025-09-18

Related Papers

Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis

Clinical Cancer Research2022-01-1960 citations

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Cancer Medicine2021-09-1611 citations

Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

Journal of Clinical Oncology2021-05-206 citations